| Featured Articles From The Current Issue |
|
|
Kevin Cancelliere, MS, believes that as the trend toward self-administration continues, the need for careful consideration of primary container design, interaction with the drug product, method of administration, and end-user needs becomes even more criti
|
|
|
|
Special Feature: Contributor Cindy H. Dubin speaks with prefilled syringe manufacturers as well as contract parenteral manufacturers who share their thoughts about the delivery challenges associated with high-viscous, high-volume formulations.
|
|
|
|
Ronnda L. Bartel, PhD, Tod Borton, and Brian S. Hampson review how Aastrom Biosciences has developed the innovative processes necessary to reduce risk throughout the manufacturing process. The company is now preparing for future commercialization for its
|
|
|
|
Marshall Crew, PhD, President & CEO, Agere Pharmaceuticals, Inc., begins his multiple-part series discussing today's most challenging issues in solubility.
|
|
|
|
Drug Development Executive: Dr. Shunji Haruta, Founder of NDS (Nasal Delivery Systems) Division and Executive Officer, SNBL, Ltd., discusses how NDS Division and its powder nasal delivery platform, μco SystemTM, fit into a new paradigm.
|
|
|
|
Philip J. Butler and Thorsten Cech investigate the gastric-resistant functionality obtained by applying a clear, two-component MAE coating formulation onto a tablet sub-coated with a pigmented instant-release coating and investigate the impact of hydrophi
|
|
|
|
Jemma Lampkin and Gerard Loosschilder, PhD, show how Monte Carlo-based forecasts are better at handling uncertainties, turning them into valuable tools for product managers and marketers engaged in strategic business planning.
|
|
|
|
Derek G. Hennecke continues with part 4 of a new 6-part series offering an overview of this year's best business books with insights into what they can teach the Pharma industry.
|
|
|
|
Frost & Sullivan Analyst, Cecilia Van Cauwenberghe, MS, examines the observed trends in particle design and engineering technologies, as well as the main factors and opportunities driving the principal technological advances in the biopharmaceutical indus
|
|
|
|
John A. Bermingham explains how it is incumbent upon CEOs and their management teams to triage all functional areas of the company when in times of trouble and the investors are looking for a quick fix to stop the bleeding.
|
|
|
|
Kenneth B. Kirby and Chandan A.S. Alam, MD, are part of a team at Transdermal Delivery Solutions Corp. (TDSC) that has been leveraging its patented technology to develop a unique patchless, metered pump, spray-on drug delivery system and products.
|
|
|
 
| Market News & Trends |
 |
 
 
| Whitepapers / Webinars |
|
|
|
| Industry Events |
|
|
 
|
Executive Summary: Martin Driscoll, CEO of Asmacure, talks about his company's unique, yet practical approach to treating asthma and its core symptoms.
|
|
|
|
Drug Development Executive: Marshall Crew, President & CEO of Agere, discusses how the company is taking a different approach that leverages expertise, but relies heavily on the principles of physical chemistry to enable automation.
|
|
|
|
|
| Resource Directory |
|
| Featured Technologies & Services |
|
|
Clinical Development Serivces
Vetter Development Service (VDS) provides expert support for your drug development projects, from inception to market launch........
Solid Dosage Forms
Agere Pharmaceuticals offers clients formulation design and development, cGMP analytical, and solid oral dosage form services....
Tamper-Resistant Formulation Technology
INTAC®, Grünenthal's tamper-resistant formulation technology, is designed to deter a number of relevant routes of abuse/inadvertent misuse from tablet tampering by imposing a high mechanical stability to the tablet.
Universal Tumor Targeting
NanoSmart® Pharmaceuticals’ mission is to positively impact patients with cancer and other diseases worldwide by improving the safety and efficacy of existing pharmaceutical...
|
Coming in June
- Controlled Release Technologies Market
- Orally Disintegrating Tablets
- State of Bioavailability
- Integrating Genomic Biomarkers
- Innovative Device Design
- Mucoadhesive Drug Delivery
CONTACTS
Ralph Vitaro
rvitaro@drug-dev.com
973-299-1200
John Kieswetter
jkiesewetter@drug-dev.com
541-338-0022
Patricia Loyas
ployas@drug-dev.com
518-668-4144
|
|